Peter U. Park

2.3k total citations
39 papers, 1.8k citations indexed

About

Peter U. Park is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Peter U. Park has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Peter U. Park's work include Monoclonal and Polyclonal Antibodies Research (25 papers), HER2/EGFR in Cancer Research (17 papers) and Glycosylation and Glycoproteins Research (5 papers). Peter U. Park is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (25 papers), HER2/EGFR in Cancer Research (17 papers) and Glycosylation and Glycoproteins Research (5 papers). Peter U. Park collaborates with scholars based in United States, Guam and France. Peter U. Park's co-authors include Victor S. Goldmacher, Yulius Y. Setiady, Jennifer A. Coccia, Robert J. Lutz, Hans K. Erickson, Yelena Kovtun, Wayne C. Widdison, Lisa M. Garrett, Walter A. Blättler and Pierre‐Antoine Defossez and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Peter U. Park

38 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter U. Park United States	15	737	687	504	334	219	39	1.8k
David V. Gold United States	29	936 1.3×	883 1.3×	637 1.3×	431 1.3×	79 0.4×	67	2.0k
Clark Q. Pan United States	23	1.0k 1.4×	282 0.4×	397 0.8×	227 0.7×	179 0.8×	47	1.9k
Miyako Abe United States	17	1.3k 1.8×	473 0.7×	624 1.2×	482 1.4×	37 0.2×	20	1.7k
Brian G. Van Ness United States	24	1.2k 1.7×	405 0.6×	306 0.6×	936 2.8×	385 1.8×	68	2.1k
Mikhail A. Nikiforov United States	30	2.1k 2.8×	580 0.8×	140 0.3×	274 0.8×	149 0.7×	69	2.8k
Enrico Fontanella Italy	26	1.8k 2.5×	1.1k 1.6×	93 0.2×	331 1.0×	211 1.0×	40	2.6k
G T Stevenson United Kingdom	26	932 1.3×	413 0.6×	1.2k 2.5×	1.1k 3.3×	241 1.1×	98	2.3k
Joseph T.Y. Lau United States	34	2.1k 2.8×	218 0.3×	334 0.7×	1.2k 3.5×	124 0.6×	74	2.7k
C. Jones United States	30	1.3k 1.8×	300 0.4×	225 0.4×	366 1.1×	247 1.1×	66	2.3k
Evert de Vries Netherlands	29	1.4k 1.8×	865 1.3×	242 0.5×	1.4k 4.2×	82 0.4×	55	2.8k

Countries citing papers authored by Peter U. Park

Since Specialization

Citations

This map shows the geographic impact of Peter U. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter U. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter U. Park more than expected).

Fields of papers citing papers by Peter U. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter U. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter U. Park. The network helps show where Peter U. Park may publish in the future.

Co-authorship network of co-authors of Peter U. Park

This figure shows the co-authorship network connecting the top 25 collaborators of Peter U. Park. A scholar is included among the top collaborators of Peter U. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter U. Park. Peter U. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Palacino, James, Pedro Lee, Yeonjoon Kim, et al.. (2023). Abstract 2700: ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML. Cancer Research. 83(7_Supplement). 2700–2700. 5 indexed citations

Rigby, Michael, Gavin Bennett, Liuhong Chen, et al.. (2022). BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors. Molecular Cancer Therapeutics. 21(12). 1747–1756. 41 indexed citations

Palacino, James, Yong Yi, Anna Skaletskaya, et al.. (2022). Abstract 3933: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer. Cancer Research. 82(12_Supplement). 3933–3933. 19 indexed citations

Mudd, Gemma, Liuhong Chen, Katerine Van Rietschoten, et al.. (2022). Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer. Journal of Medicinal Chemistry. 65(21). 14337–14347. 58 indexed citations

Rigby, Mike, Paul Beswick, Gemma Mudd, et al.. (2019). Abstract 4479: BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models. Cancer Research. 79(13_Supplement). 4479–4479. 6 indexed citations

Bennett, Gavin, Philip Huxley, Amy Brown, et al.. (2018). Abstract 5855: Bicycle Drug Conjugates targeting EphA2 for the treatment of solid tumors: Discovery and selection of BT5528. Cancer Research. 78(13_Supplement). 5855–5855. 2 indexed citations

Gumerov, Dmitry R., Dongmei Xiao, Joshua D. Thomas, et al.. (2016). Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC). Cancer Research. 76(14_Supplement). 596–596. 2 indexed citations

Bergstrom, Donald A., Natalya D. Bodyak, Peter U. Park, et al.. (2015). Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors. Cancer Research. 75(15_Supplement). LB–231. 12 indexed citations

Deckert, Jutta, Marie-Cécile Wetzel, Laura M. Bartle, et al.. (2014). SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research. 20(17). 4574–4583. 245 indexed citations

10.

Deckert, Jutta, Peter U. Park, Yong Weon Yi, et al.. (2013). A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood. 122(20). 3500–3510. 67 indexed citations

11.

Deckert, Jutta, Michele Mayo, Yong Weon Yi, et al.. (2011). Abstract 4565: IMGN529: A therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia. Cancer Research. 71(8_Supplement). 4565–4565. 4 indexed citations

12.

Setiady, Yulius Y., Jennifer A. Coccia, & Peter U. Park. (2009). In vivo depletion of CD4⁺FOXP3⁺ Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII⁺ phagocytes. European Journal of Immunology. 40(3). 780–786. 187 indexed citations

13.

Park, Peter U., Véronique Blanc, Jutta Deckert, et al.. (2008). SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies. Blood. 112(11). 2756–2756. 3 indexed citations

14.

Erickson, Hans K., Peter U. Park, Wayne C. Widdison, et al.. (2006). Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing. Cancer Research. 66(8). 4426–4433. 421 indexed citations

15.

Arnoult, Damien, Laura M. Bartle, Anna Skaletskaya, et al.. (2004). Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proceedings of the National Academy of Sciences. 101(21). 7988–7993. 165 indexed citations

16.

Park, Peter U., Mitch McVey, & Leonard Guarente. (2002). Separation of mother and daughter cells. Methods in enzymology on CD-ROM/Methods in enzymology. 351. 468–477. 47 indexed citations

17.

Park, Peter U., Pierre‐Antoine Defossez, & Leonard Guarente. (1999). Effects of Mutations in DNA Repair Genes on Formation of Ribosomal DNA Circles and Life Span in Saccharomyces cerevisiae. Molecular and Cellular Biology. 19(5). 3848–3856. 125 indexed citations

18.

Harrigan, George G., Hendrik Luesch, Wesley Y. Yoshida, et al.. (1999). Tumonoic Acids, Novel Metabolites from a Cyanobacterial Assemblage of Lyngbya majuscula and Schizothrix calcicola. Journal of Natural Products. 62(3). 464–467. 22 indexed citations

19.

Nagle, Dale G., Peter U. Park, & Valerie J. Paul. (1997). Pitiamide A, a new chlorinated lipid from a mixed marine cyanobacterial assemblage. Tetrahedron Letters. 38(40). 6969–6972. 21 indexed citations

20.

Radicella, J. Pablo, Mark A. Fox, & Peter U. Park. (1995). Response : Adaptive Mutation and Sex. Science. 269(5222). 288–288. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact